4-chloro-N-phenyl-1,3,5-triazin-2-amine | 746673-85-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-chloro-N-phenyl-1,3,5-triazin-2-amine
• 英文别名: (4-Chloro-[1,3,5]triazin-2-yl)-phenyl-amine
• CAS: 746673-85-8
• 化学式: C₉H₇ClN₄
• 分子量: 206.634
• InChiKey: JFJOEUGRBAQXDG-UHFFFAOYSA-N

物化性质

• 沸点：
  401.5±28.0 °C(Predicted)
• 密度：
  1.404±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  50.7
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-chloro-N-phenyl-1,3,5-triazin-2-amine 、 2,4,6-三甲酚 在 四丁基硫酸氢铵 、 sodium hydroxide 作用下， 以 水 、 甲苯 为溶剂， 反应 0.5h， 以69.7 mg的产率得到4-(mesityloxy)-N-phenyl-1,3,5-triazin-2-amine
  参考文献：
  名称：

  Optimization of the pharmacokinetic properties of potent anti-trypanosomal triazine derivatives

  摘要：

  Human African trypanosomiasis is causing thousands of deaths every year in the rural areas of subsaharan Africa. There is a high unmet medical need since the approved drugs are poorly efficacious, show considerable toxicity and are not easy to administer. This work describes the optimization of the pharmacokinetic properties of a previously published family of triazine lead compounds. One compound (35 (UAMC-03011)) with potent anti-trypanosomal activity and no cytotoxicity was selected for further study because of its good microsomal stability and high selectivity for Trypanosoma brucei over a panel including Trypanosoma cruzi, Leishmania infantum, and Plasmodium falciparum. In vivo pharmacokinetic parameters were determined and the compound was studied in an acute in vivo mouse disease model. One of the important leamings of this study was that the rate of trypanocidal activity is an important parameter during the lead optimization process. (C) 2018 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2018.03.048
• 作为产物：
  描述：

  2,4-二氯-1,3,5-三嗪 、 苯胺 在 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 0.5h， 生成 4-chloro-N-phenyl-1,3,5-triazin-2-amine
  参考文献：
  名称：

  TANK-BINDING KINASE INHIBITOR COMPOUNDS

  摘要：

  具有以下化学式（I）的化合物以及它们的使用和制备方法已被披露：

  公开号：

  US20160096827A1

文献信息

• TANK-BINDING KINASE INHIBITOR COMPOUNDS
  申请人：Gilead Sciences, Inc.

  公开号：US20160096827A1

  公开（公告）日：2016-04-07

  Compounds having the following formula (I) and methods of their use and preparation are disclosed:

  具有以下化学式（I）的化合物以及它们的使用和制备方法已被披露：
• [EN] 4-ARYL-N-PHENYL-1,3,5-TRIAZIN-2-AMINES CONTAINING A SULFOXIMINE GROUP<br/>[FR] 4-ARYL-N-PHÉNYL-1,3,5-TRIAZINE-2-AMINES CONTENANT UN GROUPE SULFOXIMINE
  申请人：BAYER IP GMBH

  公开号：WO2012160034A1

  公开（公告）日：2012-11-29

  The present invention relates to 4-aryl-N-phenyl-1,3,5-triazin-2-amines containing a sulfoximine group of general formula (I) or (Ia) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I) or (Ia).

  本发明涉及一种含有一般式(I)或(Ia)中所述和定义的亚砜基团的4-芳基-N-苯基-1,3,5-三嗪-2-胺，以及它们的制备方法，它们用于治疗和/或预防疾病，特别是高增殖性疾病和/或病毒诱导的传染病和/或心血管疾病。该发明还涉及在制备所述一般式(I)或(Ia)化合物中有用的中间化合物。
• [EN] SUBSTITUTED 4-ARYL-N-PHENYL-1,3,5-TRIAZIN-2-AMINES<br/>[FR] 4-ARYL-N-PHÉNYL-1,3,5-TRIAZINE-2-AMINES SUBSTITUÉES
  申请人：BAYER IP GMBH

  公开号：WO2012143399A1

  公开（公告）日：2012-10-26

  The present invention relates to substituted 4-Aryl-N-phenyl-1,3,5-triazin-2-amines of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I).

  本发明涉及通式（I）所述和定义的取代的4-芳基-N-苯基-1,3,5-三嗪-2-胺，以及其制备方法，其用于治疗和/或预防疾病，特别是高增殖性疾病和/或病毒诱导的传染病和/或心血管疾病。该发明还涉及在制备通式（I）所述化合物中有用的中间化合物。
• [EN] HETEROARYL SUBSTITUTED PYROLLS USEFUL AS INHIBITORS OF PROTEIN KINASES<br/>[FR] PYRROLES A SUBSTITUTION HETEROARYLE SERVANT D'INHIBITEURS DE PROTEINES KINASES
  申请人：VERTEX PHARMA

  公开号：WO2004072063A1

  公开（公告）日：2004-08-26

  The present invention provides compounds that are inhibitors of protein kinase, particularly inhibitors of ERK2, GSK3, PKA, CDK2 protein kinases, mammalian protein kinases involved in proliferative and neurodegenerative disorders. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of utilizing those compositions in the treatment of various disorders.

  本发明提供了一种抑制蛋白激酶的化合物，特别是抑制ERK2、GSK3、PKA、CDK2蛋白激酶的化合物，这些是参与增殖性和神经退行性疾病的哺乳动物蛋白激酶。该发明还提供了包括本发明化合物的药物组合物，以及利用这些组合物治疗各种疾病的方法。
• 4-ARYL-N-PHENYL-1,3,5-TRIAZIN-2-AMINES CONTAINING A SULFOXIMINE GROUP
  申请人：Lücking Ulrich

  公开号：US20140315906A1

  公开（公告）日：2014-10-23

  The present invention relates to 4-aryl-N-phenyl-1,3,5-triazin-2-amines containing a sulfoximine group of general formula (I) or (Ia) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I) or (Ia).

  本发明涉及一种含有磺酰亚胺基团的4-芳基-N-苯基-1,3,5-三嗪-2-胺的一般式(I)或(Ia)，以及其制备方法，其用于治疗和/或预防疾病，特别是高增殖性疾病和/或病毒引起的传染病和/或心血管疾病。本发明还涉及用于制备上述一般式(I)或(Ia)化合物的中间体化合物。